Wockhardt Files EMA Application for Novel Antibiotic WCK 5222

13 Jan 2026 CW Team

Wockhardt has filed a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA) for its novel antibiotic WCK 5222, marking a significant milestone in the company’s global regulatory journey. The application was submitted on January 5, 2026, positioning the drug for scientific evaluation across 27 European Union member states and three European Economic Area countries—Norway, Iceland and Liechtenstein—covering a total of 30 nations.

The EMA, which is responsible for the centralised assessment of new medicines in Europe, had earlier informed Wockhardt that WCK 5222 qualifies for the Accelerated Assessment pathway. This provision enables a shortened review timeline for therapies that address serious unmet medical needs, underlining the clinical importance of the antibiotic in combating resistant infections.

WCK 5222 is a fixed-dose combination of Zidebactam (1 g) and Cefepime (2 g), developed to treat severe Gram-negative bacterial infections that are resistant to existing therapies. The product is already under fast-track review by the US Food and Drug Administration, reflecting growing global regulatory recognition of its potential clinical value.

Based on the clinical and regulatory data submitted, Wockhardt anticipates approval of WCK 5222 for the treatment of multidrug-resistant Gram-negative infections across all countries under the EMA’s jurisdiction. The priority status accorded to the application highlights the urgent global need for effective treatment options for patients suffering from life-threatening infections caused by antimicrobial resistance.

Notably, WCK 5222 is the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation, reinforcing India’s growing capabilities in advanced pharmaceutical research and innovation.

Infrastructure Urban

04 Aug 2026

TCC Concept Reports 480% Revenue Growth in Q1FY27

TCC Concept has reported strong financial performance for the first quarter of FY27, with revenue from operations rising 480% year-on-year to Rs 1,283 million.The company’s EBITDA increased 158% year-on-year to Rs 463 million, with an EBITDA margin of 36.1%. Profit after tax (PAT) grew 34% year-on-year to Rs 126 million during the quarter.The growth was supported by continued execution across TCC’s integrated ecosystem spanning consumer commerce, supply chain, digital infrastructure, cloud, PropTech and AI-led platforms.Pepperfry continued to strengthen its omnichannel expansion stra..

ANHAD Developers Appoints Akash Lakhina as Sales Head

ANHAD Developers has appointed Akash Lakhina as Head of Sales, Marketing and CRM as the company strengthens its leadership team ahead of its entry into Gurugram’s premium residential market.The appointment follows Adil Altaf taking charge as CEO of the group’s real estate vertical. Lakhina will be responsible for driving the company’s sales, marketing and customer relationship initiatives for its upcoming luxury developments.With nearly three decades of professional experience, Lakhina brings expertise across multiple industries, including over a decade in luxury real estate. His experie..

BXB Estates Records AED 110 Million Luxury Villa Sale in Dubai

BXB Estates has completed a record AED 110 million residential transaction at Jumeirah Golf Estates, marking the highest-value residential sale in the history of one of Dubai’s most prestigious communities.The transaction, negotiated by Alfie Tabrez, Managing Partner, BXB Estates, surpasses the previous record of AED 58 million for a completed ready villa.The six-bedroom luxury residence features a built-up area of 21,714 sq ft on a 15,873 sq ft plot. The property includes nine bathrooms, four living lounges, a home office, bar lounge, private cinema and rooftop terrace. Its wellness facilit..